Vecuronium

證據等級: L5

預測適應症: 2 個

Vecuronium: From Neuromuscular Blockade to Insomnia

One-Sentence Summary

Vecuronium is a non-depolarising neuromuscular blocking agent used in surgical and intensive care settings to facilitate endotracheal intubation and maintain skeletal muscle relaxation during general anaesthesia. The TxGNN model predicts it may be effective for Insomnia, with 0 clinical trials and 0 publications directly supporting this direction — the single trial identified is a general paediatric pharmacokinetics study entirely unrelated to sleep disorders. This prediction is mechanistically implausible and is not recommended for further development at this time.

Quick Overview

Item	Content
Original Indication	No CBG-MEB authorisation on record; known clinical use is neuromuscular blockade in anaesthesia/ICU
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.34%
Evidence Level	L5
NL Market Status	Not marketed in the Netherlands
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current Evidence Pack. Based on established pharmacology, Vecuronium is a non-depolarising neuromuscular blocking agent that competitively antagonises nicotinic acetylcholine receptors (nAChR) at the peripheral skeletal neuromuscular junction, producing reversible paralysis of voluntary muscles. It is administered exclusively by intravenous injection in controlled hospital environments (operating theatres, ICU), has negligible lipid solubility, and does not cross the blood-brain barrier.

Insomnia is a central nervous system disorder driven by dysregulation of sleep-wake circuits involving GABAergic, adenosinergic, histaminergic, and orexin/hypocretin pathways. None of these pathways involve peripheral nAChR activity. Vecuronium has no direct action on any CNS target known to regulate sleep architecture.

The high TxGNN score (99.34%) is likely an artefact of indirect knowledge-graph path inference — specifically the chain “neuromuscular blockade → sedation assistance → sleep improvement” — which does not constitute a clinically or pharmacologically translatable mechanism. No preclinical or clinical evidence supports repurposing Vecuronium for insomnia, and this prediction should be treated as a false positive generated by graph topology rather than biological plausibility.

Clinical Trial Evidence

One trial was retrieved, but its relevance to insomnia is Grade C (not relevant). Vecuronium appears in this study solely as a standard-of-care anaesthetic agent; the study does not investigate sleep disorders.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01431326	N/A	Completed	3,520	Broad paediatric pharmacokinetics observational study covering multiple understudied drugs administered per standard of care. Vecuronium was included as a routine anaesthetic/ICU agent. Primary endpoints are PK parameters. No relation to insomnia treatment.

Literature Evidence

Currently no related literature available.

Netherlands Market Information

Vecuronium holds no CBG-MEB marketing authorisation in the Netherlands. There are no registered products, RVG numbers, or approved indications on record.

RVG Number	Product Name	Dosage Form	Approved Indication
—	No authorised products	—	—

Note: In other EU/EEA markets, Vecuronium bromide (e.g., Norcuron) has been authorised as a short-acting neuromuscular blocking agent for surgical use. If market entry in the Netherlands is under consideration for any indication, a full CBG-MEB or centralised EMA authorisation pathway would be required from the outset.

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) for safety information. No key warnings, contraindications, or drug interaction data are available in the current Evidence Pack.

Important context for evaluators: Vecuronium is a Schedule 4 / high-alert medication in most jurisdictions. It requires controlled administration with ventilatory support capability on hand due to the risk of respiratory muscle paralysis. This context makes any proposed outpatient or self-administered use (as would be typical for insomnia treatment) pharmacologically and practically incompatible.

Conclusion and Next Steps

Decision: Hold

Rationale: Vecuronium’s mechanism of action — peripheral nAChR antagonism causing skeletal muscle paralysis — has no established or plausible link to the central pathways governing sleep-wake regulation. The single identified clinical trial is entirely unrelated to insomnia (Grade C), and there is no supporting literature. The drug is also not marketed in the Netherlands (0 CBG-MEB authorisations), and all safety data remain unavailable. This combination of mechanistic implausibility, zero targeted evidence, non-marketed status, and safety data gaps makes further pursuit unjustifiable at this stage.

To proceed, the following would be required:

Identification of a biologically plausible mechanism linking peripheral nAChR antagonism (or a secondary pharmacological property of Vecuronium) to CNS sleep-wake regulation — this currently does not exist in the literature
At minimum one peer-reviewed publication or registered prospective clinical trial specifically investigating Vecuronium (or a closely related neuromuscular blocking agent) for insomnia
Full resolution of Blocking data gaps: SmPC/safety data must be retrieved (from EMA product information or equivalent) before any further safety screening (Stage S1) can be initiated
Regulatory feasibility assessment: given non-marketed status in the Netherlands, a de-novo CBG-MEB authorisation pathway would need to be scoped
Re-evaluation of the second TxGNN prediction (Irritable Bowel Syndrome, score 99.11%) — which also carries a “Hold / no plausible mechanism” assessment — before committing any resources to this candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.